Open AccessNMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region
Author(s) -
Jixun Dai,
Ding Chen,
Roger Jones,
Laurence H. Hurley,
Danzhou Yang
Publication year - 2006
Publication title -
nucleic acids research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.008
H-Index - 537
eISSN - 1362-4954
pISSN - 0305-1048
DOI - 10.1093/nar/gkl610
Subject(s) - antiparallel (mathematics) , g quadruplex , biology , footprinting , dna footprinting , folding (dsp implementation) , intramolecular force , gene , dna , biophysics , promoter , stereochemistry , genetics , transcription factor , gene expression , chemistry , physics , quantum mechanics , magnetic field , electrical engineering , engineering
BCL2 protein functions as an inhibitor of cell apoptosis and has been found to be aberrantly expressed in a wide range of human diseases. A highly GC-rich region upstream of the P1 promoter plays an important role in the transcriptional regulation of BCL2. Here we report the NMR solution structure of the major intramolecular G-quadruplex formed on the G-rich strand of this region in K+ solution. This well-defined mixed parallel/antiparallel-stranded G-quadruplex structure contains three G-tetrads of mixed G-arrangements, which are connected with two lateral loops and one side loop, and four grooves of different widths. The three loops interact with the core G-tetrads in a specific way that defines and stabilizes the overall G-quadruplex structure. The loop conformations are in accord with the experimental mutation and footprinting data. The first 3-nt loop adopts a lateral loop conformation and appears to determine the overall folding of the BCL2 G-quadruplex. The third 1-nt double-chain-reversal loop defines another example of a stable parallel-stranded structural motif using the G3NG3 sequence. Significantly, the distinct major BCL2 promoter G-quadruplex structure suggests that it can be specifically involved in gene modulation and can be an attractive target for pathway-specific drug design.